Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Sequencing Algorithms for Umbralisib-Based Therapy in MZL and FL

May 18th 2021

Experts in the management of lymphoma discuss how umbralisib fits into sequencing algorithms and highlight how treatment decisions are particularly complex in MZL compared to FL.

Off-the-Shelf Allogeneic Cell Therapy Shows Early Promise in Relapsed/Refractory CD30+ Lymphoma

May 14th 2021

An off-the-shelf, allogeneic CD30-CAR Epstein Barr virus–specific T-cell therapy has demonstrated favorable safety and encouraging clinical activity, even when given at lower dose levels, in patients with relapsed/refractory CD30-positive lymphoma.

Dr. Caimi on the FDA Approval of Loncastuximab Tesirine in R/R Large B-Cell Lymphoma

May 14th 2021

Paolo F. Caimi, MD, discusses the FDA approval of loncastuximab tesirine-lpyl in relapsed/refractory large B-cell lymphoma.

Next-Generation Tissue Factor–Targeting ADC XB002 to be Examined in Several Solid Tumors

May 12th 2021

The safety, tolerability, pharmacokinetics, and preliminary antitumor activity of the novel agent XB002 is set to be examined in an upcoming phase 1 clinical trial that is expected to begin the second quarter of 2021.

Combination Therapy With Umbralisib in MZL and FL

May 11th 2021

Lori A. Leslie, MD, and Anthony Mato, MD, MSCE, comment on the potential safety and efficacy of the PI3K inhibitor umbralisib in combination with a CD20 antibody in marginal zone and follicular lymphoma.

The UNITY-NHL Trial of Umbralisib in MZL and FL

May 11th 2021

Key opinion leaders in hematology-oncology discuss the recent UNITY-NHL trial and the FDA’s accelerated approval of umbralisib in relapsed/refractory marginal zone lymphoma and follicular lymphoma.

Rapid Readouts: Results from the Phase 3 CHRONOS-3 Trial for Relapsed iNHL

May 7th 2021

Tycel J. Phillips, MD, presents slides from the American Association for Cancer Research (AACR) Virtual Annual Meeting 2021 of results from the phase 3 CHRONOS-3 study of copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (iNHL).

Dr. Alkharabsheh on Future Research Directions in MPNs

May 5th 2021

Omar Alkharabsheh, MD, discusses future research directions for the treatment of patients with myeloproliferative neoplasms.

Emerging Combinations for FLT3-Mutated AML

May 5th 2021

Jessica K. Altman, MD, and Naval G. Daver, MD, review novel combinations under investigation for the treatment of FLT3-mutated acute myeloid leukemia.

BCL2 Inhibitor Combinations in FLT3-Mutated AML

May 5th 2021

A discussion on the use of venetoclax combinations with FLT3 inhibitors, especially in older patients with FLT3-mutated acute myeloid leukemia.

Dr. Grunwald on the Established and Potential Utility of Tisagenlecleucel in ALL

May 5th 2021

Michael R. Grunwald, MD, FACP, discusses the established and potential utility of tisagenlecleucel in patients with acute lymphoblastic leukemia.

Dr. Grunwald on Preventing Relapse in Lymphoid and Myeloid Malignancies

May 4th 2021

Michael R. Grunwald, MD, FACP, discusses preventing relapse in patients with lymphoid and myeloid malignancies following allogeneic transplantation.

Dr. Ansell on Challenges With PET Scans in Hodgkin Lymphoma

May 4th 2021

Stephen M. Ansell, MD, PhD, discusses challenges with positron emission tomography scans in patients with Hodgkin lymphoma.

Unmet Needs in GVHD

May 4th 2021

Challenges and unmet needs in steroid-refractory GVHD and advice to community oncologists for the optimal management of disease.

Safety and Efficacy of PI3K Inhibitors in MZL and FL

May 4th 2021

Expert hematologist-oncologists share insights about the role of PI3K inhibition and immunosuppression in indolent non-Hodgkin lymphoma and review the safety and efficacy of idelalisib, duvelisib, and copanlisib.

Second-Line Chemoimmunotherapy for MZL and FL

May 4th 2021

Anthony Mato, MD, MSCE, and Lori A. Leslie, MD, consider treatment options for patients with relapsed/refractory disease after first-line chemoimmunotherapy.

Emerging Therapies for Acute and Chronic GVHD

May 4th 2021

Novel agents in the pipeline for the treatment of acute and chronic GVHD are discussed.

FDA Approval Insights: Liso-Cel in Refractory Large B-Cell Lymphoma

May 3rd 2021

Dr. Abramson discusses the significance of the FDA approval of lisocabtagene maraleucel in refractory large B-cell lymphoma and provided insight into the efficacy and safety profiles of the CAR T-cell therapy as reported in the TRANSCEND NHL 001 trial.

DPX-Survivac/Pembrolizumab Plus Cyclophosphamide to Be Examined in DLBCL

May 3rd 2021

Following feedback from the FDA, IMV Inc. and Merck have entered into an agreement to open a phase 2b clinical trial examining the combination of maveropepimut-S and pembrolizumab plus low-dose cyclophosphamide in patients with recurrent/refractory diffuse large B-cell lymphoma.

Sequential CD19-Directed CAR T-Cell Therapy and Allogeneic Transplant Provide Long-Term Responses in Pediatric B-ALL

April 30th 2021

Sequential therapy with CD19.28ζ-directed CAR T cells followed by allogeneic hematopoietic stem cell transplant induced durable disease control in a significant population of children and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.